In a healthy term infant born at 38 weeks gestation who is 13 days old, at what total serum bilirubin level should phototherapy be initiated?

Phototherapy Threshold for a 13-Day-Old Term Infant

For a healthy 38-week infant at 13 days of age (312 hours), phototherapy should be initiated when total serum bilirubin (TSB) reaches approximately 20 mg/dL (342 μmol/L), based on the most recent 2024 AAP guidelines that use hour-specific thresholds adjusted for gestational age and neurotoxicity risk factors. 1

Key Decision Points

Age-Based Threshold Application

• At 13 days of life (>72 hours), this infant falls into the oldest age category where phototherapy thresholds are highest 2
• The 2024 AAP guidelines emphasize intensive phototherapy at thresholds based on gestational age, neurotoxicity risk factors, and age of the infant in hours 1
• For infants >72 hours old without risk factors, the threshold is 20 mg/dL 2

Critical Assessment Requirements

• TSB (not transcutaneous bilirubin) must be used as the definitive diagnostic test to guide all treatment interventions 1
• If transcutaneous bilirubin (TcB) is within 3.0 mg/dL of the phototherapy threshold, exceeds the threshold, or is ≥15 mg/dL, confirm with TSB 1
• TcB measurements are not accurate enough to determine treatment decisions, though they are good screening tests 1

Important Clinical Considerations

Evaluate for Pathologic Jaundice

At 13 days of age, persistent jaundice warrants investigation for underlying causes 1:

• Measure G6PD enzyme activity if jaundice cause is unknown, TSB rises despite intensive phototherapy, TSB rises suddenly after initial decline, or escalation of care is needed 1
• Assess for hemolytic disease, metabolic disorders, or other pathologic causes 1

Rate of Rise Assessment

• If multiple TSB measurements are available, calculate the rate of rise 1
• A rapid rise ≥0.2 mg/dL per hour after 24 hours of age is exceptional and suggests ongoing hemolysis 1
• This would warrant more aggressive intervention regardless of absolute TSB level 1

Treatment Implementation

Home vs. Hospital Phototherapy

• For infants already discharged who develop TSB above the phototherapy threshold, home LED-based phototherapy is an option if specific criteria are met 1
• Home phototherapy with comprehensive support (daily lactation support and blood draws) successfully treats hyperbilirubinemia in the vast majority of cases (98.1% success rate) 3
• This approach can avoid readmission and reduce healthcare costs significantly 4

Monitoring During Treatment

• For hospitalized infants, measure TSB to verify efficacy after starting phototherapy 1
• Timing of TSB testing should be guided by the TSB trajectory (rate of rise) and infant age 1

Discontinuation Criteria

• Discontinue phototherapy when TSB has declined by 2 to 4 mg/dL below the hour-specific threshold at which phototherapy was initiated 1
• For this 13-day-old infant, follow-up TSB should be measured within 1 to 2 days after phototherapy discontinuation 1
• Note that infants <38 weeks gestation require more intensive follow-up (8-12 hours post-discontinuation) 1

Common Pitfalls to Avoid

Do Not Rely on TcB for Treatment Decisions

• While TcB is useful for screening, all treatment decisions must be based on TSB levels 1
• This is critical to prevent both under-treatment and over-treatment 1

Escalation of Care Threshold

• Escalate care when TSB is at or above the exchange transfusion threshold or within 0 to 2 mg/dL below it 1
• Infants requiring escalation should receive IV hydration and emergent intensive phototherapy immediately 1
• Measure TSB at least every 2 hours during the escalation period 1

Risk of Rebound Hyperbilirubinemia

• The risk of rebound is lower at 13 days compared to younger infants, but still requires follow-up 1
• Infants with hemolytic disease or positive DAT require closer monitoring even at this age 1